Seagen wins future royalties in Enhertu patent dispute

[cafead]

via Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in damages, in an ongoing patent dispute.

article source